Corrective Phases R...
Health Care: Drugs
Delcath Systems Inc. (DCTH: NASDAQ)
$1.46 0.02 | 1.39%
06/04/12 - 11:55 AM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 25.78M | 45.62M | 35.49M | 10.79M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 31.99M | 48.90M | 36.29M | 11.34M |
| Property, Plant & Equipment, Gross | 4.76M | 2.16M | 546.29K | 17.00K |
| Accumulated Depreciation & Depletion | 1.51M | 477.42K | 24.98K | 0.00 |
| Property, Plant & Equipment, Net | 3.25M | 1.68M | 521.31K | 17.00K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Assets | 3.25M | 1.68M | 521.31K | 17.00K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 35.24M | 50.58M | 36.81M | 11.36M |
| Accounts Payable | 925.00K | 610.46K | 1.84M | 703.00K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 2.44M | 18.01M | 11.21M | 448.00K |
| Total Current Liabilities | 8.84M | 21.20M | 13.05M | 1.15M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 300.00K | 300.00K | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 300.00K | 300.00K | 0.00 | 0.00 |
| Total Liabilities | 9.14M | 21.50M | 13.05M | 1.15M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 26.10M | 29.08M | 23.76M | 10.21M |
| Common Par | 482.00K | 430.28K | 362.23K | 254.00K |
| Additional Paid In Capital | 172.61M | 144.78M | 92.84M | 57.29M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -146.94M | -116.06M | -69.37M | -47.32M |
| Treasury Stock | -51.00K | -51.10K | -51.10K | 0.00 |
| Other Equity Adjustments | 0.00 | -26.20K | -16.20K | -24.00K |
| Total Capitalization | 26.10M | 29.08M | 23.76M | 10.21M |
| Total Equity | 26.10M | 29.08M | 23.76M | 10.21M |
| Total Liabilities & Stock Equity | 35.24M | 50.58M | 36.81M | 11.36M |
| Total Common Shares Outstanding | 48.02M | 42.93M | 36.19M | 25.38M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 28.10K | 28.10K | 28.10K | 28.00K |
| Basic Weighted Shares Outstanding | 45.24M | 38.99M | 27.07M | 25.30M |
| Diluted Weighted Shares Outstanding | 45.24M | 38.99M | 27.07M | 25.30M |
| Number of Employees | 80 | 47 | 17 | 6 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with DCTH
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserROSIE
- UserTA stocks
- ContributorBarron's Activist Stocks 8-...
- UserSUPRATRADE 7 Top Stocks for...
- UserASCO 2010
- Contributor10 Biotech Stocks on Clinic...
- ContributorBarron's Insider Purchases ...
- User52 Week High Strategy
Latest DCTH Headlines from TheStreet
- BIO CEO Confab Live Blog: Day 2 02.14.12 | 10:02 am
- Biotech Stock Mailbag: Mela Sciences 09.09.11 | 06:09 am
- Biotech Calendar: Key Dates for September 08.31.11 | 06:08 am
- Biotech Stock Mailbag: Celsion 05.13.11 | 08:05 am
- 'Mad Money Lightning Round': Go for Exelixis 04.26.11 | 07:04 pm
- Biotech Stock Mailbag: Amarin 04.22.11 | 07:04 am
- Sweet Spot in Biotech Investing 04.13.11 | 12:04 pm
- Delcath: Safety Questions Behind FDA Delay 02.23.11 | 07:02 am
- Delcath Hit With FDA Approval Delay 02.22.11 | 10:02 am
- 10 Health Care Stocks With 100% Buy Ratings 01.28.11 | 07:01 am
Press Releases for DCTH
- Delcath Announces First CHEMOSAT Procedures In Germany - PR Newswire 02.27.12 | 06:02 am
- Delcath Announces Updated Efficacy Results From Phase 3 Trial Of Chemosaturation For Melanoma Metastases In The Liver Presented At European Multidisciplinary Cancer Congress - PR Newswire 09.23.11 | 06:09 pm
- Positive Phase 2 Trial Results From Neuroendocrine Tumor Cohort Presented At CIRSE - PR Newswire 09.13.11 | 02:09 am
- Delcath Systems Receives Refusal To File Letter From FDA - PR Newswire 02.22.11 | 05:02 am
- Delcath Achieves ISO 13485 Certification - PR Newswire 02.17.11 | 09:02 am
- Delcath Completes New Drug Application Submission To The FDA For The Chemosaturation Delivery System - PR Newswire 12.22.10 | 07:12 am
- Delcath Submits CE Mark Technical File For Hepatic ChemoSAT⢠Delivery System - PR Newswire 12.06.10 | 06:12 am
- Delcath Names Bernard R. Tyrrell As Senior Vice President For North American Sales And Marketing - PR Newswire 12.01.10 | 06:12 am
- Encompass Fund’s Go-Anywhere Strategy Continues To Excel In 2010 - Business Wire 11.10.10 | 05:11 pm
- Delcath Systems Announces Third Quarter Progress Report Conference Call - PR Newswire 10.27.10 | 06:10 am
Partner Headlines for DCTH
- Active Stock Alerts: Dendreon, Delcath Systems, Johnson & Johnson, Boeing, Onyx June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- Hyper-Novel Investments For Targeting Cancer - Seeking Alpha 05.30.12 | 09:05 am
- Mid-Day Update: Stocks Trending Water Ahead of First Holiday Weekend of Summer - NASDAQ 05.25.12 | 04:05 pm
- Mid-Day Market Losers - Benzinga 05.25.12 | 01:05 pm
- 4 Stocks Attracting Heavy Trading Interest - Wall St. Cheat Sheet 05.25.12 | 12:05 pm
- Ultimate Market Recap: Talbots Tanks, Facebook Fiasco Continues - Wall St. Cheat Sheet 05.25.12 | 06:05 am
- Company News for January 03, 2012 - Corporate Summary - Zacks 01.03.12 | 10:01 am
- Emisphere: Crown Jewel In Oral B12 - Seeking Alpha 10.07.11 | 09:10 am
- Delcath Announces Updated Efficacy Results from Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver - Benzinga 09.23.11 | 06:09 pm
- Friday's Top Performing Small Cap Stocks (MDS, MNKD, FXCM, FOE, DCTH) - NASDAQ 08.15.11 | 01:08 pm
